William Maisel News Today

Using a swab inside the cheek and a sophisticated computer algorithm, a DNA test recently approved by federal regulators promises to assess genetic risk of opioid addiction. The test’s maker

The FDA is taking a second stab at banning the use of electroshock devices in patients with intellectual and developmental disorders.

FDA is proposing a ban of electrical stimulation devices (ESDs) intended to reduce or stop self-injurious or aggressive behavior, a step rarely taken by the agency

Federal regulators are taking a second stab at banning the controversial use of electroshock devices to manage the behavior of patients with intellectual and developmental disorders.

/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a new...

CDRH is pleased to announce that we have been operating under normal review timelines for all incoming premarket submissions for almost a year, and we’re accepting all submission types for review.

Duodeonoscopes, the technology at the heart of several superbug outbreaks, have been a problem for decades, the FDA issue guidance cleaning only Thursday.

Top House lawmakers wrote to the director of the FDA Center for Biologics Evaluation and Review, asking why the agency so frequently issues clinical trial holds to experimental cell and gene therapies.

The two federal programs intended to compensate people injured by vaccines or pandemic countermeasures are fielding thousands of claims unlikely to be resolved — or paid out — anytime soon.

The announcement from the Food and Drug Administration follows years of pressure from disability rights groups and mental health experts who have called the treatment outdated, ineffective and unethical.